CRON Cronos Group Inc.

Nasdaq Medicinal Chemicals & Botanical Products A1 CIK: 0001656472
AI RATING
SELL
72% Confidence

Investment Thesis

Cronos Group faces structural profitability challenges with operating margins of -4.1% and severe revenue contraction of -24.2% YoY, despite a fortress balance sheet. While the company has $821.9M in cash and positive free cash flow, these are being consumed by an unprofitable core business with deteriorating earnings (EPS down 118.2% YoY) and weak capital returns (ROE 1.3%, ROA 1.2%).

Strengths

  • + Fortress balance sheet with $821.9M cash and zero debt (Debt/Equity 0.00x)
  • + Positive free cash flow generation of $9.0M with 20% FCF margin
  • + Strong liquidity position with current ratio of 21.87x
  • + Gross margins of 42.4% indicate viable product economics at the production level

Risks

  • ! Revenue declining 24.2% YoY indicates loss of market share or demand contraction in a highly competitive sector
  • ! Operating loss of -$1.8M with -4.1% operating margin shows core business is unprofitable; positive net income appears driven by one-time items, not sustainable operations
  • ! Severe earnings deterioration with EPS down 118.2% YoY signals fundamental business deterioration
  • ! Extremely poor capital efficiency with ROE of 1.3% and ROA of 1.2% despite $1.1B in equity; cash reserves are not generating returns
  • ! Large divergence between operating income (-$1.8M) and net income ($13.8M) suggests reliance on non-recurring gains or accounting adjustments

Key Metrics to Watch

Financial Metrics

Revenue
45.2M
Net Income
13.8M
EPS (Diluted)
$0.04
Free Cash Flow
9.0M
Total Assets
1.2B
Cash
821.9M

Profitability Ratios

Gross Margin 42.4%
Operating Margin -4.1%
Net Margin 30.4%
ROE 1.3%
ROA 1.2%
FCF Margin 20.0%

Balance Sheet & Liquidity

Current Ratio
21.87x
Quick Ratio
20.73x
Debt/Equity
0.00x
Debt/Assets
4.1%
Interest Coverage
-141.00x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-13T08:12:16.993607 | Data as of: 2026-03-31 | Powered by Claude AI